Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeWitt, P. A.
Right arrow Articles by Calne, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LeWitt, P. A.
Right arrow Articles by Calne, D. B.
NEUROLOGY 1983;33:1009
© 1983 American Academy of Neurology

Comparison of pergolide and bromocriptine therapy in parkinsonism

P. A. LeWitt, MD, C. D. Ward, MD, T. A. Larsen, MD, M. I. Raphaelson, MD, R. P. Newman, MD, N. Foster, MD, J. M. Dambrosia, PhD and D. B. Calne, DM, FRCP

Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke (Drs. LeWitt, Ward, Larsen, Raphaelson, Newman, Foster, and Calne), Bethesda, MD, and the Office of Biometry and Field Studies, National Institute of Neurological and Communicative Disorders and Stroke (Dr. Dambrosia), Bethesda, MD.

Twenty-four parkinsonian patients compared pergolide and bromocriptine therapy in a randomized double-blind, two-period crossover study. Both drugs were adjusted to an optimal balance between benefits and side effects. The mean daily dose and dose range for pergolide and bromocriptine were 3.3 mg (0.7 to 7.2) and 42.7 mg (5.8 to 87.5), respectively. Adjunctive medications, which for most patients included levodopa (plus carbidopa), were not altered during the study. A similar spectrum of clinical effects was found with both drugs and with lisuride, which was used to treat 13 of the patients in a previous study. Despite neurochemical differences in the antiparkinsonian ergots, their clinical utility is quite similar. We draw attention to hepatotoxicity and pleural reactions that may occur rarely with these drugs.

Address correspondence and reprint requests to Dr. LeWitt, Building 10, Room 5C101, National Institutes of Health, Bethesda, MD 20205.

Accepted for publication December 22, 1982.




This article has been cited by other articles:


Home page
 J. Am. Med. Inform. Assoc.Home page
E. S. Chen, G. Hripcsak, H. Xu, M. Markatou, and C. Friedman
Automated Acquisition of Disease Drug Knowledge from Biomedical and Clinical Documents: An Initial Study
J. Am. Med. Inform. Assoc., January 1, 2008; 15(1): 87 - 98.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. W. Olanow, R. L. Watts, and W. C. Koller
An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment
Neurology, June 12, 2001; 56(suppl_5): S1 - S88.
[Full Text] [PDF]

Home page
 NeurologyHome page
C. G. Goetz, L. Blasucci, and G. T. Stebbins
Switching dopamine agonists in advanced Parkinson's disease: Is rapid titration preferable to slow?
Neurology, April 1, 1999; 52(6): 1227 - 1227.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. B. Calne
Treatment of Parkinson's Disease
N. Engl. J. Med., September 30, 1993; 329(14): 1021 - 1027.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by AAN Enterprises, Inc.